» Articles » PMID: 26433702

Simplified 2-tier Histologic Grading System Accurately Predicts Outcomes in Goblet Cell Carcinoid of the Appendix

Overview
Journal Hum Pathol
Specialty Pathology
Date 2015 Oct 5
PMID 26433702
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Goblet cell carcinoid (GCC) is a rare appendiceal malignancy with both neuroendocrine and glandular features. Clinical outcomes of patients with GCC vary widely and a histology-based 3-tiered prognostic scheme has been previously suggested; however, this scheme is subjective and challenging to apply in day-to-day practice. We sought to construct a simplified and prognostic grading system based on objective histologic features with specific criteria. A continuous population-based cohort of GCC with clinical outcome data and archival tissue available for review was extracted from regional databases. For the 78 patients with confirmed appendiceal GCC, specific histologic features, including cytologic atypia, peritumoral stromal desmoplasia, and solid growth pattern, were recorded, and a scoring system was devised, which separates patients with GCC into low-grade (n = 55; 71%) or high-grade (n = 23; 29%) histology. Correspondingly, clinical follow-up data show good prognosis in those with low-grade histology with median and 10-year overall survival of 51.0 months and 80.5%, respectively, whereas those with high-grade histology have a poor prognosis with median and 10-year overall survival of 16.5 months (P = .006) and 0% (P < .001), respectively. Multivariate Cox proportional hazard modeling demonstrates that this 2-tier histologic system remains predictive of overall survival when controlled for TNM clinicopathological stage. These data show that a simple and objective histologic scoring system separates GCC into low- and high-grade histology with divergent clinical outcomes.

Citing Articles

Appendiceal Goblet Cell Carcinoma: Role of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Gaillard M, Van Eyken P, Verswijvel G, Van der Speeten K Indian J Surg Oncol. 2023; 14(Suppl 1):240-249.

PMID: 37359931 PMC: 10284751. DOI: 10.1007/s13193-023-01748-2.


Goblet Cell Carcinoma of the Appendix with Synchronous Adenocarcinoma of the Cecum: Distinct or Related Entities?.

Vincenti L, Andriola V, Cazzato G, Colagrande A, Fiore F Diseases. 2022; 10(4).

PMID: 36278575 PMC: 9590081. DOI: 10.3390/diseases10040077.


Incidental discovery of goblet cell carcinoid, a rare appendiceal malignancy case report.

Barbash D, Trivedi A, Yang J, Nguyen R, Huribal J, Zuberi J J Surg Case Rep. 2022; 2022(7):rjac356.

PMID: 35919700 PMC: 9341438. DOI: 10.1093/jscr/rjac356.


Goblet Cell Adenocarcinoma of the Appendix: A Systematic Review and Incidence and Survival of 1,225 Cases From an English Cancer Registry.

Palmer K, Weerasuriya S, Chandrakumaran K, Rous B, White B, Paisey S Front Oncol. 2022; 12:915028.

PMID: 35903705 PMC: 9314749. DOI: 10.3389/fonc.2022.915028.


New insights in the pathology of peritoneal surface malignancy.

Carr N J Gastrointest Oncol. 2021; 12(Suppl 1):S216-S229.

PMID: 33968439 PMC: 8100698. DOI: 10.21037/jgo-2020-01.